Involving Ige Or Igd Patents (Class 424/805)
-
Patent number: 10759860Abstract: This disclosure relates generally to an EGFR antibody and its therapeutic effects on tumor inhibition in vitro and in vivo, alone or in combination with various chemotherapeutic agents. In particular, the present disclosure relates to methods for the treatment of cancer, comprising administering an EGFR antibody, alone or in combination with a chemotherapeutic agent.Type: GrantFiled: September 15, 2015Date of Patent: September 1, 2020Assignee: Synermore Biologics Co., Ltd.Inventor: Eric Tsao
-
Patent number: 8999339Abstract: The present invention provides methods of treating a mammal having chronic obstructive pulmonary disease (COPD), independent of both smoking status and asthma status, with a therapeutically effective amount of an anti-IgE moiety. In accordance with the invention, COPD patients with an elevated serum IgE level may benefit from the treatment methods disclosed. In certain instances, the methods of the disclosure have been found to be useful for the treatment of COPD patients regardless of their skin test results and/or in vitro reactivity to a perennial aeroallergen. Anti-IgE moieties, in accordance with the invention, include but are not limited to any IgG antibody that selectively binds to a given mammal immunoglobulin E (e.g., human immunoglobulin E) such as humanized anti-IgE, humanized murine monoclonal antibody, and/or Omalizumab.Type: GrantFiled: June 6, 2014Date of Patent: April 7, 2015Inventor: Clifford G. Risk
-
Patent number: 8974794Abstract: The invention pertains to methods of using C?mX peptides (e.g., GLAGGSAQSQRAPDRVL; SEQ ID NO:2) that can bind effectively induce immune responses to membrane-bound IgE (mIgE) expressed on the surface of human B lymphocytes.Type: GrantFiled: April 16, 2014Date of Patent: March 10, 2015Assignee: Academia SinicaInventors: Tse Wen Chang, Jiun-Bo Chen, Pheidias C. Wu, Alfur F. Hung
-
Patent number: 8968738Abstract: Methods of using anti-FceRI or anti-IgE antibodies for treating an autoimmune disease are disclosed. Also disclosed is a composition comprising an anti-FceRI antibody or anti-IgE antibody for use in treating an autoimmune disease. Also disclosed are non-antibody compounds that specifically activate basophils and/or mast cells, either by cross-linking IgE or FceRI, or by activating the cells through an FceRI-independent pathway and methods of using the same to treat autoimmune diseases.Type: GrantFiled: September 14, 2011Date of Patent: March 3, 2015Assignee: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.Inventors: Edward E. Mitre, Marc P. Hübner
-
Patent number: 8961992Abstract: Epsi-gam provides a novel fusion protein with the ability to cross-link either of the Fc?RI or Fc?RII cell surface receptors with an Fc?RIIb cell surface receptor in order to block IgE-mediated biological responses.Type: GrantFiled: April 2, 2014Date of Patent: February 24, 2015Assignee: Tunitas Therapeutics, Inc.Inventors: Nolan Sigal, Gizette Sperinde
-
Patent number: 8945566Abstract: The invention provides a method for increasing the bioactivity (e.g. the biosafety and efficacy) of a therapeutic IgE antibody of the invention in the treatment of a patient. Methods of the invention include: i) administering to the patient a therapeutic IgE antibody in combination with at least one bioactivity-enhancing agent, ii) strategic treatment regimens and protocols for the dosing and administration of a therapeutic IgE antibody of the invention, and iii) the use of a therapeutic IgE antibody having a variable region comprising at least one antigen binding region specific for binding an epitope of an antigen wherein the epitope is not highly repetitive or is non-repetitive.Type: GrantFiled: April 26, 2012Date of Patent: February 3, 2015Assignee: Quest PharmaTech, Inc.Inventors: Birgit C. Schultes, Christopher F. Nicodemus
-
Patent number: 8865179Abstract: A method is disclosed wherein an antigenic B-cell epitope is discovered by in vitro transcription and translation of pre-determined sequence on thermostable protein scaffolds detected by antibodies to a native protein. Immune reactivities of IgE B-cell epitopes from pre-determined IgE sequences from the constant region, engaged in binding to high affinity IgE Fc receptors, placed in a loop of green fluorescent protein (GFP) were shown immuno-reactive with anti-IgE. Moreover, the antigenic B-cell epitope can be further optimized by molecular evolution, selected by conformer antibody and receptor on solid phase via ribosome display. Alternatively, a random aptameric antigenic sequence inserted into a loop of the protein scaffold, mimicking a pre-determined sequence of a native protein, can be selected by solid phase conformer antibody and receptor via ribosome display.Type: GrantFiled: January 26, 2008Date of Patent: October 21, 2014Assignee: Swey-Shen AlexchenInventor: Swey-Shen Alex Chen
-
Patent number: 8828394Abstract: This invention relates to methods of treating IgE mediated disorders such as allergy and asthma based on activating surface-bound IgD molecules on basophils. The invention also relates to methods of making IgD, as well as methods of screening for antimicrobial agents from IgD-activated basophils.Type: GrantFiled: April 1, 2010Date of Patent: September 9, 2014Assignee: Cornell UniversityInventors: Andrea Cerutti, Kang Chen
-
Patent number: 8765134Abstract: The present invention provides methods of treating a mammal having chronic obstructive pulmonary disease (COPD), independent of both smoking status and asthma status, with a therapeutically effective amount of an anti-IgE moiety. In accordance with the invention, COPD patients with an elevated serum IgE level may benefit from the treatment methods disclosed. In certain instances, the methods of the disclosure have been found to be useful for the treatment of COPD patients regardless of their skin test results and/or in vitro reactivity to a perennial aeroallergen. Anti-IgE moieties, in accordance with the invention, include but are not limited to any IgG antibody that selectively binds to a given mammal immunoglobulin E (e.g., human immunoglobulin E) such as humanized anti-IgE, humanized murine monoclonal antibody, and/or Omalizumab.Type: GrantFiled: November 28, 2011Date of Patent: July 1, 2014Inventor: Clifford G. Risk
-
Patent number: 8741294Abstract: The invention pertains to the generation and utility of antibodies that can bind effectively to C?mX domain on membrane-bound IgE (mIgE) expressed on the surface of human B lymphocytes. The C?mX domain of 52 amino acid residues, located between the CH4 domain and the C-terminal membrane-anchor peptide on human membrane-bound epsilon chain, had been suggested as an antigenic site for immunological targeting of B cells expressing mIgE. Previous reported monoclonal antibodies, including a20, which bind to RADWPGPP (SEQ ID NO:1) peptide at the C-terminal of C?mX, have now been found to bind poorly to mIgE on human B cells. We have discovered that only monoclonal antibodies specific for certain segments, such as GLAGGSAQSQRAPDRVL (SEQ ID NO:2) and HSGQQQGLPRAAGGSVPHPR (SEQ ID NO:3), of C?mX can bind effectively to mIgE on human B cells and hence have the utility for targeting those B cells for the treatment of diseases mediated by IgE.Type: GrantFiled: May 7, 2013Date of Patent: June 3, 2014Assignee: Academia SinicaInventors: Tsewen Chang, Jiun-Bo Chen, Pheidias C. Wu, Alfur F. Hung
-
Patent number: 8722053Abstract: The present invention relates to the provision of novel immunogens comprising an antigenic IgE peptide preferably linked to an immunogenic carrier, compositions comprising the immunogens, and methods for the prevention, treatment or alleviation of IgE-mediated disorders. The invention further relates to methods for production of these medicaments, immunogenic compositions and pharmaceutical compositing thereof and their use in medicine.Type: GrantFiled: June 2, 2011Date of Patent: May 13, 2014Assignee: Pfizer Vaccines LLCInventors: Brian Robert Champion, David Robert Stead, Paul Andrew Wright
-
Patent number: 8697079Abstract: The present invention provides monoclonal IgE antibodies comprising Fc epsilon (?) constant regions and variable regions comprising at least one antigen binding region specific for binding a single epitope of a circulating, tumor-associated antigen (TAA) that is not a cell surface antigen wherein the epitope of the targeted antigen is not highly repetitive or is a non-repetitive epitope. The IgE antibodies of the invention are useful in the treatment of cancer associated with the tumor antigen. In one embodiment the TAA is prostate-specific antigen (PSA).Type: GrantFiled: February 14, 2012Date of Patent: April 15, 2014Assignees: Quest Pharma Tech Inc., The Regents of the University of CaliforniaInventors: Manuel L. Penichet, Birgit C. Schultes, Christopher F. Nicodemus, Tracy R. Daniels, Gustavo Helguera, Jose A. Rodriguez
-
Patent number: 8632775Abstract: The present application relates to apoptotic anti-IgE antibodies, nucleic acid encoding the same, therapeutic compositions thereof, and their use in the treatment of IgE-mediated disorders.Type: GrantFiled: October 25, 2011Date of Patent: January 21, 2014Assignee: Genentech, Inc.Inventors: Lawren Wu, Mercedesz Balazs, Hans Brightbill, Andrew Chan, Yvonne Chen, Anan Chuntharapai, Mark Dennis, Terence Wong
-
Patent number: 8618274Abstract: The present application relates to apoptotic anti-IgE antibodies, nucleic acid encoding the same, therapeutic compositions thereof, and their use in the treatment of IgE-mediated disorders.Type: GrantFiled: October 25, 2011Date of Patent: December 31, 2013Assignee: Genentech, Inc.Inventors: Lawren Wu, Mercedesz Balazs, Hans Brightbill, Andy Chan, Yvonne Chen, Anan Chuntharapai, Mark Dennis, Terence Wong
-
Patent number: 8586040Abstract: The present application relates to apoptotic anti-IgE antibodies, nucleic acid encoding the same, therapeutic compositions thereof, and their use in the treatment of IgE-mediated disorders.Type: GrantFiled: October 25, 2011Date of Patent: November 19, 2013Assignee: Genentech, Inc.Inventors: Lawren Wu, Mercedesz Balazs, Hans Brightbill, Andy Chan, Yvonne Chen, Anan Chuntharapai, Mark Dennis, Terence Wong
-
Patent number: 8563258Abstract: The invention pertains to a method for the determination of basophil activation induced by a test substance by flow cytometric measurement of the changes of the mean or median fluorescence intensities (MFI) of the basophilic Fc?RI receptor present on the cell surface of basophils (MFI-Fc?RI) and/or the IgE antibodies bound to the Fc?RI receptor (MFI-IgE), and the CD63 antigen exposed on the cell surface of basophils after their activation (MFI-CD63), by means of a mixture of anti-CD63, anti-Fc?RI or anti-IgE, and anti-CCR3 antibodies each labelled with a distinct fluorophore, of which at least one antibody acts as a basophil selection marker and at least two antibodies act as basophil activation markers, and bringing the mean fluorescence intensities of the activation markers in correlation to obtain an Activation Index.Type: GrantFiled: September 11, 2008Date of Patent: October 22, 2013Assignee: Buhlmann Laboratories AGInventors: Jean Sainte-Laudy, Michael Schneider, Jakob Matthias Weber
-
Patent number: 8475801Abstract: The present invention relates to the provision of novel immunogens comprising an antigenic IgE peptide preferably linked to an immunogenic carrier for the prevention, treatment or alleviation of IgE-mediated disorders. The invention further relates to methods for production of these medicaments, immunogenic compositions and pharmaceutical compositing thereof and their use in medicine.Type: GrantFiled: August 1, 2012Date of Patent: July 2, 2013Assignee: Pfizer Vaccines, LCCInventors: Alan Daniel Brown, Brian Robert Champion, Clare Christy, David Paul Gervais, Lyn Howard Jones, Anne Maria Kristina Kjerrstrom, David Cameron Pryde, Lee Richard Roberts, David Michael Wyatt
-
Patent number: 8475793Abstract: The invention relates to binding compounds that specifically bind to human TSLPR, as well as uses thereof, e.g., in the treatment of inflammatory disorders.Type: GrantFiled: February 6, 2009Date of Patent: July 2, 2013Assignee: Merck Sharp & Dohme Corp.Inventors: Rene De Waal Malefyt, Leonard G. Presta
-
Patent number: 8460664Abstract: The invention pertains to the generation and utility of antibodies that can bind effectively to C?mX domain on membrane-bound IgE (mIgE) expressed on the surface of human B lymphocytes. The C?mX domain of 52 amino acid residues, located between the CH4 domain and the C-terminal membrane-anchor peptide on human membrane-bound epsilon chain, had been suggested as an antigenic site for immunological targeting of B cells expressing mIgE. Previous reported monoclonal antibodies, including a20, which bind to RADWPGPP (SEQ ID NO:1) peptide at the C-terminal of C?mX, have now been found to bind poorly to mIgE on human B cells. We have discovered that only monoclonal antibodies specific for certain segments, such as GLAGGSAQSQRAPDRVL (SEQ ID NO:2) and HSGQQQGLPRAAGGSVPHPR (SEQ ID NO:3), of C?mX can bind effectively to mIgE on human B cells and hence have the utility for targeting those B cells for the treatment of diseases mediated by IgE.Type: GrantFiled: February 25, 2010Date of Patent: June 11, 2013Assignee: Academia SinicaInventors: Tsewen Chang, Jiun-bo Chen, Pheidias C Wu, Alfur F Hung
-
Patent number: 8450068Abstract: The present invention provides an assay for detecting serum IgE antibody levels to cetuximab and to other proteins. The present invention further provides a method for predicting whether a subject will respond adversely to cetuximab treatment. The present further provides a method for detecting sensitivity to compounds comprising galactose-alpha-1,3-galactose.Type: GrantFiled: February 15, 2008Date of Patent: May 28, 2013Assignee: University of Virginia Patent FoundationInventors: Thomas A. E. Platts-Mills, Tina Hatley Merritt
-
Patent number: 8440412Abstract: The present invention provides a complex of an antigen and IgE binding to the antigen, a composition including an antigen and IgE binding to the antigen, and a method of using the complex or the composition to screen candidate therapeutics for TH-2 type diseases, for example in animal models.Type: GrantFiled: October 26, 2009Date of Patent: May 14, 2013Assignee: Hyogo College of MedicineInventors: Kenji Nakanishi, Tomohiro Yoshimoto
-
Patent number: 8435517Abstract: The present invention relates to immunoglobulins that bind IgE and Fc?RIIb with high affinity, said compositions being capable of inhibiting cells that express membrane-anchored IgE. Such compositions are useful for treating IgE-mediated disorders, including allergies and asthma.Type: GrantFiled: September 17, 2009Date of Patent: May 7, 2013Assignee: Xencor, Inc.Inventors: John R. Desjarlais, Seung Y. Chu, Holly M. Horton, Matthew J. Bernett
-
Patent number: 8404236Abstract: The present invention relates to the discovery of antibodies that bind to novel epitopes present on membrane-anchored immunoglobulins and which bind to these novel epitopes on the surface of B cells and plasma cells. In addition, the antibodies of the present invention can mediate ADCC and can be useful to deplete those B cells and plasma cells expressing the novel epitopes of the invention. The antibodies of the present invention can be useful for the treatment of B cell-mediated diseases and diseases caused by monoclonal expansion of B cells. Accordingly the present invention also provides compositions and methods for the prevention, management, treatment or amelioration of B cell-mediated diseases and diseases caused by monoclonal expansion of B cells.Type: GrantFiled: February 13, 2012Date of Patent: March 26, 2013Assignee: MedImmune, LLCInventors: Herren Wu, Peter Kiener, Partha S. Chowdhury, James F. Young
-
Patent number: 8389704Abstract: This invention relates to binding members, especially antibody molecules, for IgE. The binding members are useful for, inter alia, treatment of disorders mediated by IgE including allergies and asthma.Type: GrantFiled: February 15, 2008Date of Patent: March 5, 2013Assignee: MedImmune LimitedInventors: Duncan Cochrane, Suzanne Cohen, Louise Claire Dobson, Fredick Per-Olof Eriksson, David Phillip Monk, Karin Von-Wachenfeldt
-
Patent number: 8343504Abstract: The present invention relates generally to methods and materials for treating conditions associated with IgE activation in humans and animals, and to agents capable of modulating the activation. The agents of the invention comprise or are related to IGBPMA polypeptides from ticks.Type: GrantFiled: October 26, 2006Date of Patent: January 1, 2013Assignee: Natural Environment Research CouncilInventors: Hui Wang, Patricia Anne Nuttall
-
Patent number: 8298547Abstract: The present invention relates to the provision of novel immunogens comprising an antigenic IgE peptide preferably linked to an immunogenic carrier for the prevention, treatment or alleviation of IgE-mediated disorders. The invention further relates to methods for production of these medicaments, immunogenic compositions and pharmaceutical compositing thereof and their use in medicine.Type: GrantFiled: December 9, 2009Date of Patent: October 30, 2012Assignee: Pfizer Vaccines, LLCInventors: Alan Daniel Brown, Brian Robert Champion, Clare Christy, David Paul Gervais, Lyn Howard Jones, Anne Maria Kristina Kjerrstrom, David Cameron Pryde, Lee Richard Roberts, David Michael Wyatt
-
Patent number: 8273356Abstract: The present invention provides compositions and methods for the use of antigenic peptides derived from the Fc portion of the epsilon heavy chain of an IgE molecule as vaccines for the treatment and prevention of IgE-mediated allergic disorders. In particular, the invention provides compositions, methods for the treatment and prevention of IgE-mediated allergic disorders comprising an immunogenic amount of one or more antigenic peptides derived from the CH3 domain or junction of Ch-3/CH4 domain of an IgE molecule and methods for the evaluation of IgE mediated allergies in dogs.Type: GrantFiled: November 24, 2009Date of Patent: September 25, 2012Assignee: Pfizer Inc.Inventors: Mohamad A. Morsey, Michael G. Sheppard, David W. Wheeler
-
Patent number: 8236514Abstract: In certain embodiments, the present invention relates to methods, compositions, and kits for diagnosing autoimmune chronic urticaria. For example, in certain embodiments, such methods generally comprise detecting the presence of auto-antibodies to cell-surface IgE receptors or cell-bound IgE in a patient.Type: GrantFiled: October 7, 2010Date of Patent: August 7, 2012Assignee: Viracor-IBT Laboratories, Inc.Inventors: John Frederick Halsey, Michelle Lee Altrich
-
Patent number: 8137670Abstract: The present invention relates to the discovery of antibodies that bind to novel epitopes present on membrane-anchored IgE and which bind to these novel epitopes on the surface of B cells and plasma cells. In addition, the antibodies of the present invention can mediate ADCC and can be useful to deplete those B cells and plasma cells expressing the novel epitopes of the invention. The antibodies of the present invention can be useful for the treatment of IgE-mediated diseases. Accordingly the present invention also provides compositions and methods for the prevention, management, treatment or amelioration of IgE-mediated diseases.Type: GrantFiled: September 28, 2006Date of Patent: March 20, 2012Assignee: MedImmune, LLCInventors: Herren Wu, Peter Kiener, Partha S. Chowdhury, James F. Young
-
Patent number: 8080249Abstract: The present invention provides methods of treating a mammal having chronic obstructive pulmonary disease (COPD), independent of both smoking status and asthma status/with a therapeutically effective amount of an anti-IgE Ênoiety. In accordance with the invention, COFD patients with sn elevated serum IgE level may benefit from the treatment methods disclosed. In certain instances, the methods of the disclosure have been found, to be useful ioÊ the treatment of COPD patients regardless of their skin test results arid/or in vitro reactivity to a perennial aeroallergen. Anti-ÊgE moieties, in accordance With the invention, include but are not limited to any IgG antibody that selectively binds to a given mammal iirunuitoglobulln E (e.g., human imntnnoglQbulin E) such as humanized arrti-IgEy humanized murine monoclonal antibody, and/or Qmalizumab.Type: GrantFiled: June 30, 2006Date of Patent: December 20, 2011Inventor: Glifford G. Risk
-
Patent number: 7959917Abstract: This invention relates to binding members, especially antibody molecules, for IgE. The binding members are useful for, inter alia, treatment of disorders mediated by IgE including allergies and asthma.Type: GrantFiled: February 15, 2008Date of Patent: June 14, 2011Assignee: MedImmune LimitedInventors: Duncan Cochrane, Suzanne Cohen, Claire Louise Dobson, Per-Olof Eriksson, Karin Von Wachenfeldt, Phillip David Monk
-
Patent number: 7931898Abstract: The invention provides methods and compositions for inhibiting binding of IgE to a high affinity receptor. The methods and compositions are useful in the treatment of allergic diseases and allergy symptoms in mammals.Type: GrantFiled: May 9, 2008Date of Patent: April 26, 2011Assignee: IDEXX Laboratories, Inc.Inventors: Eugene Regis Krah, III, Robert Lawton
-
Patent number: 7897151Abstract: The present invention provides compositions and methods for the use of antigenic peptides derived from the Fc portion of the epsilon heavy chain of an IgE molecule as vaccines for the treatment and prevention of IgE-mediated allergic disorders. In particular, the invention provides compositions, methods for the treatment and prevention of IgE-mediated allergic disorders comprising an immunogenic amount of one or more antigenic peptides derived from the CH3 domain or junction of Ch-3/CH4 domain of an IgE molecule and methods for the evaluation of IgE mediated allergies in dogs.Type: GrantFiled: August 4, 2005Date of Patent: March 1, 2011Assignee: Pharmacia & Upjohn Company, LLCInventors: Mohamad A. Morsey, Michael G. Sheppard, David W. Wheeler
-
Patent number: 7867494Abstract: The present invention relates to novel human antibodies specifically directed against human immunoglobulin E (anti-IgE). The present invention also relates to pharmaceutical compositions and methods for treating asthma, in particular allergic asthma, as well as other IgE-mediated disorders including allergic rhinitis and food allergies.Type: GrantFiled: April 1, 2008Date of Patent: January 11, 2011Assignees: Amgen Fremont Inc., Pfizer Inc.Inventors: Wai Liu, Mike Yeadon, Isabelle de Mendez, Alison Logan, Gerald F. Casperson, Arvind Rajpal, Mark A. Moffat, Wei Liao, Caroline Brown, Nurten Beyaz-Kavuncu, Judith Diaz-Collier, Sirid-Aimee Kellermann
-
Patent number: 7824877Abstract: In certain embodiments, the present invention relates to methods, compositions, and kits for diagnosing autoimmune chronic urticaria. For example, in certain embodiments, such methods generally comprise detecting the presence of auto-antibodies to cell-surface IgE receptors or cell-bound IgE in a patient.Type: GrantFiled: September 10, 2007Date of Patent: November 2, 2010Assignee: Viracor-IBT Laboratories, Inc.Inventors: John Frederick Halsey, Michelle Lee Altrich
-
Patent number: 7582735Abstract: The invention relates to: nucleic acid molecules encoding the light chain and heavy chain of feline immunoglobulin E (IgE), including species-specific regions of feline IgE; proteins encoded by the nucleic acid molecules; inhibitors to the nucleic acids and proteins; antibodies to the proteins; cells transformed with the nucleic acid molecules; assays employing the transformed cells, nucleic acids, antibodies and/or proteins or portions thereof; methods for treating IgE-mediated responses (ie. allergy) using the materials provided; methods for eliciting an immune response to IgE and kits containing the nucleic acid molecules, proteins or derivatives thereof (ie. antibodies).Type: GrantFiled: February 16, 2007Date of Patent: September 1, 2009Assignee: Heska CorporationInventors: Catherine McCall, Eric Weber
-
Patent number: 7482010Abstract: The invention relates to a hypoallergenic immunogenic molecule derived from the Phl p 6 allergen, wherein the Phl p 6 molecule has an N-terminal and/or C-terminal deletion which makes the molecule at least substantially lack IgE binding capacity. The invention also relates to a hypoallergenic immunogenic combination of molecules derived from the Phl p 6 allergen, comprising (i) a Phl p 6 molecule having an N-terminal deletion which makes the molecule at least substantially lack IgE binding capacity, and (ii) a Phl p 6 molecule having a C-terminal deletion which makes the molecule at least substantially lack IgE binding capacity, which two molecules together encompass the complete sequence of Phl p 6. The invention further relates to the use of the hypoallergenic immunogenic molecule or molecule mixture in hyposensitization and diagnosis.Type: GrantFiled: November 27, 2002Date of Patent: January 27, 2009Assignee: Phadia ABInventors: Rudolf Valenta, Susanne Vrtala, Sabine Stummfoll, Hans Grönlund, Monika Grote, Luca Vangelista, Annalisa Pastore, Wolfgang R. Sperr, Peter Valent, Dietrich Kraft
-
Patent number: 7384633Abstract: An antibody or an antibody fragment is provided that is efficacious for treating allergic diseases in which IgE is involved. A human antibody and a fragment thereof to a receptor (Fc?RI) having high affinity to Fc portion of IgE was obtained using phage antibody display technique. The human anti-IgE receptor antibody and a fragment thereof of the invention has an activity to inhibit the binding between IgE and IgE receptor and hence is expected to be useful as a medicament for treating allergic diseases caused by the binding between IgE and IgE receptor.Type: GrantFiled: July 18, 2002Date of Patent: June 10, 2008Assignee: Judicial Foundation the Chemo-Sero-Therapeutic Res.Inventors: Kazuhisa Sugimura, Toshihiro Nakashima, Masaharu Torikai
-
Patent number: 6379909Abstract: The invention relates to a method of evaluating the immunological status of a subject comprising the steps of 1) determining the content of an antibody in a liquid sample from the subject using an immunoassay, wherein the reaction between the antibody of the sample and a ligand in the form of an antigen, an antibody or a hapten, the ligand being directed to the Fab region of the sample antibody, is carried out in the presence of other constituents of the sample to obtain a measurement 1, 2) determining the content of an antibody in the liquid sample using an immunoassay, wherein the reaction between the antibody of the sample and a ligand in the form of an antigen, an antibody or a hapten, the ligand being directed to the Fab region of the sample antibody, is carried out in the absence of other constituents of the sample to obtain a measurement 2, and 3) interrelating measurements 1 and 2 to express the interference and using the interference as a parameter for evaluating the immunological status of the subjeType: GrantFiled: June 24, 1999Date of Patent: April 30, 2002Assignee: Alk-Abello A/SInventors: Hans-Henrik Ipsen, Niels Johansen, R Ikke Morkeberg, Soren Bogestrand, Tine Charlotte Beck
-
Patent number: 6299875Abstract: Compositions are administered to block IgE binding to receptors and ultimately displace native IgE from mast cells and related cell types, to prevent the activation of these cells during an allergic response. The compositions consist of a pharmaceutically acceptable carrier for systemic or local administration and an amount of compound binding specifically to the Fc&egr;RI IgE binding sites, and more preferably, Fc&egr;RI and Fc&egr;RII IgE binding sites, to prevent activation and degranulation of mast cells in response to exposure to allergens. The compounds can consist of IgE molecules and fragments and modifications thereof, such as IgE fragments, humanized or single chain IgE antibodies or fragments thereof, IgE with a modified Fab, non-crosslinkable IgE, or peptidomimetics which bind to the same site on the receptor as the IgE, jointly referred to herein as “IgE fragments” unless otherwise stated.Type: GrantFiled: June 4, 1998Date of Patent: October 9, 2001Assignee: Panacea Pharmaceuticals, LLCInventors: Michael Caplan, Howard Sosin
-
Patent number: 6090384Abstract: Disclosed is an antiallergic composition comprising, as an active ingredient, a peptide which is capable of binding to human IgE, more specifically the high-affinity immunoglobulin E receptor .alpha. chain or a soluble fragment, which is capable of binding to human IgE, or the high-affinity immunoglobulin E receptor .alpha. chain. The composition is clinically useful for blocking allergic responses.Type: GrantFiled: January 24, 1997Date of Patent: July 18, 2000Assignees: Chisei RA, Yoshitomi Pharmaceuticals Industries, Ltd.Inventors: Chisei Ra, Koji Naito, Minoru Hirama, Ko Okumura
-
Patent number: 5858690Abstract: The present invention comprises a simple way of identifying the tendency towards allergy or allergy already broken out, and showing the probability of allergy in a patient, by measuring the receptor expression of the phagocytic cells of peripheral blood. With a logistic regression model a combination of variables were found which best describe the probability of allergy. Thus the invention relates to a method for detecting allergy and a test kit for accomplishing the method. The invention also relates to a sensitive and specific logistic model for determining the probability of allergy.Type: GrantFiled: May 30, 1996Date of Patent: January 12, 1999Assignee: Oy Aboatech AbInventors: Esa-Matti Lilius, Erika Isolauri, Seppo Salminen
-
Patent number: 5653980Abstract: The invention relates to a vaccine, preferably for human use, against IgE-mediated allergic reactions. The vaccine contains a protein having the entire amino acid sequence of the constant CH2-CH3 domains of the epsilon chain of the IgE molecule or a structurally stable unit of said amino acid sequence, the protein optionally being coupled to one or more heterologous carrier proteins, and optionally containing an adjuvant. The vaccine is injected, with or without adjuvant, to raise the concentration of endogenous anti-IgE antibodies in the plasma of allergy subjects. In practice, the vaccine can be used against all types of IgE-mediated allergies since the antibodies are not dependent of the antigen specificity of the IgE molecule but will reduce the total IgE pool of the subject. Therefore, the vaccine is aimed at being used for treatment of subjects having different types of IgE-mediated allergies.Type: GrantFiled: March 23, 1994Date of Patent: August 5, 1997Inventor: Lars T. Hellman